W
William A. Lawton
Researcher at Boehringer Ingelheim
Publications - 4
Citations - 2108
William A. Lawton is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Clopidogrel & Telmisartan. The author has an hindex of 4, co-authored 4 publications receiving 1966 citations.
Papers
More filters
Journal ArticleDOI
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Ralph L. Sacco,Hans-Christoph Diener,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +33 more
TL;DR: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel, and there is no evidence that either of the two treatments was superior to the other in the prevention of recurrent strokes.
Journal ArticleDOI
Telmisartan to prevent recurrent stroke and cardiovascular events.
Salim Yusuf,Salim Yusuf,Hans-Christoph Diener,Ralph L. Sacco,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +34 more
TL;DR: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.
Journal ArticleDOI
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study
Hans-Christoph Diener,Ralph L. Sacco,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon +33 more
TL;DR: In this paper, the putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, where patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80
Journal Article
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
Hans-Christoph Diener,Ralph L. Sacco,Salim Yusuf,Daniel Cotton,Stephanie Ôunpuu,William A. Lawton,Yuko Y. Palesch,Renee H Martin,Gregory W. Albers,Philip M.W. Bath,Natan M. Bornstein,Bernard P.L. Chan,Sien-Tsong Chen,Luís Cunha,Björn Dahlöf,Jacques De Keyser,Geoffrey A. Donnan,Conrado J. Estol,Philip B. Gorelick,Vivian Gu,Karin Hermansson,Lutz Hilbrich,Markku Kaste,Chuanzhen Lu,Thomas Machnig,Prem Pais,Robin S. Roberts,Skvortsova Vi,Philip Teal,Danilo Toni,Cam VanderMaelen,Thor Voigt,Michael A. Weber,Byung-Woo Yoon,Christopher F. Bladin +34 more
TL;DR: Disability due to recurrent stroke and cognitive decline in patients with ischaemic stroke were not different between the two antiplatelet regimens and were not affected by the preventive use of telmisartan.